-
Professor Dingwei Ye: Advancing Innovation in Uro-Oncology from Bench to Bedside, Sharing Chinese Expertise to Benefit Global Patients
In recent years, breakthroughs in basic research and clinical trials, particularly in combined targeted and immunotherapy strategies and the development of domestically produced novel drugs, have significantly advanced clinical practices in uro-oncology. However, transforming cutting-edge research into practical clinical applications and sharing Chinese expertise with international patients remains an ongoing challenge. The 14th Shanghai Genitourinary…
-
ASH 2024 | Dr. Jun Shi: Landmark Findings in Lymphoma—No Benefit of Auto-HCT in First CR with uMRD in MCL, and R-CHOP-like Regimens Effective for Advanced Relapsed DLBCL
The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, remains the largest and most comprehensive international academic gathering in the field of hematology. Every year, it draws leading experts and scholars from across the globe for in-depth discussions and exchanges on groundbreaking research. This year, the…
-
ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 2)
Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, ineffective hematopoiesis, refractory cytopenia, and a potential progression to acute myeloid leukemia (AML). At the 2024 Annual Meeting of the American Society of Hematology (ASH), held from December 7 to 10 in…
-
ASH 2024 | Dr. Wenming Chen Discusses Key Myeloma Research
The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, continues to be a global focal point for clinicians and researchers in hematology. As one of the most prestigious international conferences in the field, it has captured widespread attention both globally and within China. To provide timely…
-
ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 1)
Myelodysplastic Syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, manifested as ineffective hematopoiesis, refractory cytopenia, and the potential to transform into acute myeloid leukemia (AML). At the 2024 American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from…
-
ASH 2024 | Dr. Shenmiao Yang: Advances in Prognostic Factors for Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is highly heterogeneous, with patient survival ranging from a few months to several decades. Therefore, after the diagnosis of CLL, it is particularly important to conduct an accurate and comprehensive prognostic assessment for patients. At the 2024 American Society of Hematology (ASH) Annual Meeting held from December 7th to 10th, some…
-
ASH 2024 | Dr. He Huang’s Team Advances Breakthroughs in Bone Marrow Transplantation and Cellular Immunotherapy
The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As the largest and most comprehensive international academic conference in the field of hematology, ASH attracts leading global experts to discuss groundbreaking research and advancements. This year, Dr. He Huang’s team from the Bone…
-
ASH 2024 | Dr. Qian Jiang in Conversation with Dr. Jun Zhu on Leukemia Updates from Day One of ASH 2024
The 2024 Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10 in San Diego, USA. As one of the foremost global gatherings in the field of hematology, this prestigious conference attracted the attention of clinicians and researchers worldwide, including a keen audience from China. To bring the latest…
Connecting Medical Expertise through Media